Compare KRNY & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KRNY | LXRX |
|---|---|---|
| Founded | 1884 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 494.5M | 447.0M |
| IPO Year | 2005 | 2000 |
| Metric | KRNY | LXRX |
|---|---|---|
| Price | $7.59 | $1.17 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $8.00 | $3.23 |
| AVG Volume (30 Days) | 431.4K | ★ 1.7M |
| Earning Date | 01-29-2026 | 11-06-2025 |
| Dividend Yield | ★ 5.87% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $158,298,000.00 | $70,864,000.00 |
| Revenue This Year | $9.70 | $56.61 |
| Revenue Next Year | $15.22 | N/A |
| P/E Ratio | $15.96 | ★ N/A |
| Revenue Growth | 23.27 | ★ 1255.21 |
| 52 Week Low | $5.45 | $0.28 |
| 52 Week High | $7.95 | $1.66 |
| Indicator | KRNY | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 57.04 | 40.21 |
| Support Level | $7.26 | $1.12 |
| Resistance Level | $7.56 | $1.24 |
| Average True Range (ATR) | 0.16 | 0.07 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 44.09 | 24.39 |
Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.